Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Tests to Enable Early Identification of Cognitive Decline and Personalized Treatments

By LabMedica International staff writers
Posted on 01 Dec 2023

Some individuals who have endured extreme stressors like psychiatric disorders or childhood abuse and neglect can experience a variety of health issues later in life, such as depression, anxiety, and cardiovascular disease. More...

While not everyone who suffers from extreme stressors faces health complications later in life, a significant number do. For those affected, their cells tend to age more rapidly, leading to earlier physical breakdowns in the body, a phenomenon known as "accelerated biological aging." Natural aging processes typically involve a decline in cognitive functions, including memory, reasoning, executive function, and processing speed. Although global genetic research has generated mixed findings on whether accelerated biological aging kicks off early cognitive decline, previous studies suggest that early signs of cognitive decline can be identified long before they impact the quality of life. This opens up a window for early detection and intervention.

Now, a new study by researchers at Penn State (University Park, PA, USA) has unveiled genetic markers that could potentially forecast cognitive decline. According to the researchers, future blood tests might be able to detect early cell aging caused by these stressors, indicating a decline in cognitive abilities. In their study, the researchers analyzed two distinct population groups and found that accelerated biological aging might be a useful biomarker for identifying cognitive decline.

Utilizing blood samples and other medical data compiled from other studies, the researchers explored the relationship between potential genetic markers of cognitive performance, actual cognitive testing results, and the history of psychiatric disorders or childhood maltreatment. Their analysis revealed that accelerated biological aging is linked to reduced cognitive abilities and slower processing speed. However, the exact genetic markers indicating this relationship varied between the two study groups. The researchers attribute these differences to the distinct designs of the studies, suggesting that varying genetic markers could signal cognitive decline depending on the study's structure and focus.

“Understanding the connection between accelerated biological aging and cognitive decline may help researchers create treatments that help people who have experienced extreme stressors to experience better health,” said John Felt, assistant research professor in the Center for Healthy Aging and lead author of the study. “Cognitive decline can undermine your personal and professional life, especially for people who also have a psychiatric condition. Our research could lead to blood tests for early identification of cognitive decline and eventually to personalized treatments that support cognitive function in people with accelerated biological aging.”

Related Links:
Penn State 


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.